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Abstract 
BACKGROUND: Continuous glucose monitoring (CGM) devices are being increasingly used to 
monitor glycemia in people with diabetes. One advantage with CGM is the ability to monitor the 
trend of sensor glucose (SG) over time. However, there are few metrics available for assessing the 
trend accuracy of CGM devices. 
AIM: The aim of this study was to develop an easy to interpret tool for assessing trend accuracy of 
CGM data. 
METHODS: SG data from CGM were compared to hourly blood glucose (BG) measurements and 
trend accuracy was quantified using the dot product. Trend accuracy results are displayed on the 
Trend Compass, which depicts trend accuracy as a function of BG. A trend performance table and 
Trend Index (TI) metric are also proposed. The Trend Compass was tested using simulated CGM data 
with varying levels of error and variability, as well as real clinical CGM data. 
RESULTS: The results show that the Trend Compass is an effective tool for differentiating good trend 
accuracy from poor trend accuracy, independent of glycemic variability. Furthermore, the real 
clinical data shows that the Trend Compass assesses trend accuracy independent of point bias error. 
Finally, the importance of assessing trend accuracy as a function of BG level is highlighted in a case 
example of low and falling BG data, with corresponding rising SG data. 
CONCLUSIONS: This study developed a simple to use tool for quantifying trend accuracy. The 
resulting trend accuracy is easily interpreted on the Trend Compass plot, and if required, 
performance table and TI metric. 
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1.0 Background 
Continuous glucose monitoring (CGM) devices are becoming increasingly used by individuals with 
diabetes to help control their condition [1-6]. Unlike traditional self monitoring blood glucose (BG) 
devices, which offer a ‘snapshot’ of glucose concentration at the time of testing, CGMs give 
additional information about the approximate rate of change of BG, by measuring interstitial glucose 
every 1-5 minutes. This information is particularly useful for revealing abnormal glycemia, such as 
hypoglycemia or hyperglycemia, and deciding on the appropriate course of treatment [7-9]. 
However, to make good treatment decisions it is important to have good trend accuracy, not just 
good point accuracy.  
 
Trend accuracy refers to the ability of a CGM device to accurately capture the true rate-of-change or 
'shape' of glycemia over time, whereas, point accuracy assesses the discrepancy between a CGM and 
reference BG measurement at a single point in time. One important area where trend information is 
used is closed loop glycemic control, where CGM devices are coupled with insulin pumps and an 
appropriate control algorithm to provide automatic glycaemic control. Several pilot studies have 
investigated closed loop control in people with diabetes [10-12], but the methods are still being 
developed and it is not used as a standard therapy.  Another area where trend accuracy is 
particularly important is hypoglycemia alarms, which often inherently use trends to predict the 
onset of hypoglycemia [7, 13-16]. In this case, poor trend accuracy can result in a high rate of false 
alarms, or worse, missed hypoglycemic events.  
 
In these applications, trend accuracy is particularly important because even though good trend 
accuracy doesn't guarantee success, poor trend accuracy is likely to cause failure. As trend 
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dependent applications/features, such as closed loop control or hypoglycemic alarms, become more 
common in CGM devices the need for good trend accuracy increases. 
 
Many users of CGM devices are likely to be unaware of the level of trend accuracy of their particular 
device. Furthermore, studies in the literature that use CGMs or investigate CGM performance often 
report point accuracy, but rarely quantify trend accuracy [17, 18]. This could be because there are 
many methods or metrics available for assessing point accuracy, such as MAD, MARD, the Bland-
Altman plot [19], and Clarke error grid [20], but very few metrics to assess trend accuracy [21].  
 
One method that does assess CGM trend accuracy is the continuous glucose error grid analysis (CG-
EGA) [21]. CG-EGA evaluates the accuracy of continuous glucose monitoring sensors in terms of both 
point accuracy and trend (rate) accuracy. Results from the CG-EGA are presented in a table, showing 
the proportion of paired BG/SG measurements that fall into clinically acceptable, unacceptable and 
benign zones.  While the results produced by CG-EGA have been reported to be difficult to interpret 
[22], the method certainly represents a step in the right direction in terms of assessing both aspects 
of sensor accuracy.  
 
There is a need for additional trend metrics as increasing numbers of CGM devices make their way 
into the market. Both regulatory bodies and end users need to be confident that CGM devices have 
good trend accuracy, as well as good point accuracy, especially if they feature predictive 
hypoglycemic alarms based on trends. The aim of this study was to develop a metric or tool that 
could quantify trend accuracy and present the results in an intuitive plot that is easy to interpret for 
any user. This tool is intended to be used in conjunction with traditional point accuracy methods to 
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provide a more comprehensive assessment of sensor accuracy and clinical utility. This manuscript 
describes that tool: the Trend Compass.  
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2.0 Methods 
This paper focuses on introducing a novel trend metric that can be used to assess the trend accuracy 
of sensor glucose (SG) measurements from a continuous glucose monitoring device, with reference 
to BG reference measurements determined using a gold standard measurement device such as a 
Yellow Springs Instruments (YSI) chemistry analyser. 
 
2.1 Quantifying trend: 
Trend accuracy can be defined as the level of agreement between the rates-of-change of two 
independent devices measuring a single time series, over the same time period. An effective way to 
quantify trend accuracy is derived from the geometric interpretation of the dot product. The dot 
product assesses the similarity of 2 vectors A and B and is shown in Equation 1: 
𝐴 ∙ 𝐵 = ‖𝐴‖‖𝐵‖𝑐𝑜𝑠𝜃       Equation 1 
Where 𝐴 = [𝑎1 , 𝑎2] represents two measurements from a BG reference and 𝐵 = [𝑏2, 𝑏2] represent 
two CGM measurements at the same time points. Rearranging to make 𝜃 the subject gives a 
normalized measure of similarity between A and B: 
𝜃 = 𝑐𝑜𝑠−1 (
𝐴∙𝐵
‖𝐴‖‖𝐵‖
)      Equation 2 
The output of Equation 2 provides the angle (θ) between the two vectors, A and B, where a smaller 
angle is indicative of better trend accuracy. Thus, Equation 2 can be used with clinical data to 
quantify the level of trend accuracy between paired sets of BG/SG measurements, independent of 
the point bias error. The value of θ is dependent on the time interval between BG/SG samples, which 
should be held constant. This study uses a 1 hour time interval between consecutive samples of BG 
and SG. More frequent sampling such as 15 minutes can be analysed with the Trend Compass by 
using a 1 hour window, sliding at 15 minute increments. The sensitivity of the Trend Compass to 
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timing errors in the sampling frequency has not been investigated yet as this manuscript was written 
to present the overall method, which can be refined by consensus or future studies in due course. 
 
2.2 Trend Compass plot 
Overall trend accuracy from Equation 2 can be conveyed visually using the Trend Compass shown in 
Figure 1. A polar coordinate system is used. The angular coordinate depicts the trend accuracy (θ 
degrees from top or bottom vertical) and the radial coordinate shows the reference BG level (See 
Appendix A for a step-by-step guide to using the Trend Compass). Trend accuracy is plotted against 
reference BG level to show how it changes over the range of glucose values, because very good 
trend accuracy is more crucial during hypoglycemia or hyperglycemia where important treatment 
choices are potentially affected. For example, a mismatch in trend at 150mg/dL would likely lead to 
less severe complications than the same mismatch in trend at 60 mg/dL.  
 
Figure 1: The Trend Compass, used to assess the trend accuracy of a set of measurements relative to 
a corresponding reference set of measurements. Green zones show areas of good trending, and 
yellow and red zones show areas of moderate to severe clinical risk, respectively 
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
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Figure 2: Six examples of SG and BG paired measurements with their corresponding point on the 
Trend Compass. Note: comparing 'A' to 'D' shows that the constant bias has no effect on how 
trending is displayed on the Trend Compass (Both examples have perfect trend accuracy so θ=0°). 
 
The top hemisphere of the Trend Compass shows trend accuracy when the reference BG rate of 
change is ≥ 0 (BG is rising - examples F,A,B in Figure 2) and the bottom hemisphere shows trend 
accuracy when the reference BG rate of change is < 0 (BG is falling - examples C,D,E in Figure 2). 
Furthermore, the hemispheres are divided into two quadrants, which each give information about 
7 of 23 
 
the relative rate-of-change between the reference BG and the SG. For example 'B' in Figure 2 shows 
a BG change from 126 mg/dL to 148 mg/dL and an SG change from 126 mg/dL to 135 mg/dL, so the 
top-right quadrant is used. Alternatively, if the rate-of-change of SG is greater than that of BG, like 'F' 
in Figure 2, then the top-left quadrant is used. Note examples 'A' and 'D' in Figure 2 have perfect 
trend accuracy, even though there is a significant offset between SG and BG in 'A', so they are 
plotted on the vertical line between quadrants. Importantly, these examples are shown to reinforce 
that this Trend Compass assesses trend accuracy independent of point bias error, which would affect 
traditional accuracy metrics.  
 
In addition to separating the Trend Compass into four quadrants, two green zones around the 
vertical axis were added to show ‘good’ trend accuracy. To present the method, the size of the green 
zones were set at ±10° on the plot, which captured mismatches in trend of up to 20° (see note at the 
bottom of Appendix A). The size of the green zones was set with conservative acceptability in mind 
to present the method and may be changed by future users as desired, so long as it is held constant 
when comparing the trend accuracy of multiple devices. A few survey inputs from physicians suggest 
these limits are reasonable, although this was not comprehensively done and a large survey might 
be required for consensus on zone boundaries. 
 
In the radial direction, the Trend Compass has been separated into three zones to reflect the 
clinically significant glycemic zones: 1) hypoglycemia; 2) normoglycemia; and 3) hyperglycemia. The 
boundaries presented in this paper are 0 to 90 mg/dL (0-5mmol/L) for hypoglycemia, 90 to 160 
mg/dL (5-8.9mmol/L) for normoglycemia, and greater than 160 mg/dL (8.9mmol/L) for 
hyperglycemia. These zones are similar to what is widely accepted and published, but, again, may be 
changed by the user as desired. 
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Finally, four regions of the Trend Compass are coloured to highlight clinically significant zones where 
trend accuracy is most important. The yellow regions show areas where reference BG is above 160 
mg/dL (8.9mmol/L) and rising with poor trend accuracy. Hence, moderate caution should be applied. 
The red regions highlight areas where the consequences of poor trending could be far more 
significant, such as when reference BG is below 90mg/dL (5mmol/L) and falling. In both cases 
treatment decisions based on poor trending in SG data could increase the risk of adverse outcomes. 
 
2.3 Accompanying numerical trend metrics 
The Trend Compass was intended to be a visual tool that is fast and easy to interpret. The use of 
vector agreement as the basis of the Trend Compass allows direct, objective numerical comparison 
between devices. For this reason, a simple evaluation table can also be created for direct analysis, 
comparison and/or regulatory processes. Table 1 represents a simple choice to present the concept 
and it could easily be augmented as desired for analysis or regulatory purposes. 
 
Table 1: A table of metrics to accompany the Trend Compass plot. 
 
 
 
Overall trend accuracy
Percent in green
Percent in yellow
Percent in red
When BG is rising BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green
Percent outside green
When BG is falling BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green
Percent outside green
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Furthermore, analogous to mean absolute difference (MAD – a numerical metric that is frequently 
used to quantify point accuracy [2, 23, 24]) the user could present the trend accuracy using the 
Trend Index (TI), defined:  
𝑇𝐼 =
1
𝑛
∑ |𝜃(𝑖)|𝑛𝑖=1       Equation 3 
TI describes the average overall trend accuracy and a lower TI is indicative of better global trend 
accuracy. 
 
2.4 Simulated data 
To validate the Trend Compass in-silico, artificial SG and BG data sets were created in MATLAB™ (The 
Mathworks; Natick, MA). A glucose trace was created using a random walk model and normally 
distributed error was added to give hourly paired measurements. The paired measurement sets are 
used to illustrate the use of the Trend Compass. The data sets simulated four typical scenarios that 
might be encountered during real-world use: 
1. Low glucose variability patient with low sensor error 
2. Low glucose variability patient with high sensor error 
3. High glucose variability patient with low sensor error 
4. High glucose variability patient with high sensor error  
 
2.5 Clinical data 
Guardian real-TIME (Medtronic; Northridge, CA) Continuous glucose monitoring data and YSI 2300 
(YSI Inc. Yellow Springs, OH) reference BG measurements from 2 patients were used to show the 
Trend Compass in use with clinical data. Each patient was monitored for ~3 days, during which time 
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the SG was recorded every 5 minutes and BG was determined approximately every 60 minutes. BG 
measurements were paired with the SG measurement that was sampled closest to the time of BG 
sampling. Overall, the median [inter-quartile range (IQR)] sampling interval between BG 
measurements was 60 [55 - 62] minutes. Finally, this data was used to show the independence of 
this trend metric to point bias error.   
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3.0 Results 
3.1 Simulated data 
The Trend Compass was first tested using simulated paired SG and BG measurements, sampled at 1 
hour intervals. In all figures, the blue line represents simulated SG data and the red circles represent 
BG data.  
 
Figure 3 shows a low glucose variability patient, with low sensor error and the corresponding Trend 
Compass plot. The Trend Compass plot shows very good trend accuracy, with most of the points 
lying close to the vertical lines at the cardinal North (N) and South (S) position (TI = 11.3°). In the 
radial direction, the Trend Compass plot depicts the patient as a low glucose variability patient, as all 
of the points are contained within the normoglycemic band. Table 2 also shows good trend accuracy 
results for this patient with 91.3% of measurements falling within the green zones.  
 
Figure 4 shows a patient with the same glucose trace characteristics as in Figure 3, but with a higher 
level of sensor error. The increase in error has resulted in a Trend Compass plot with visibly more 
points outside the green zones (TI = 28.1°). This result is also reflected in Table 3, which reports 
39.1% of points in the green zones and 8.7% of points in the red zone.  
 
Figure 5 shows an example of a patient with high glucose variability, coupled with low sensor error. 
The Trend Compass plot for this patient appears similar to Figure 3 with majority of points near the 
N and S positions, and a similar TI of 11.1°. However, in the radial direction the points are far more 
spread out due to the large range of glucose values in the data set. Table 4 shows trend accuracy to 
be good, with 82.6% of data points in the green zones and 0% in the yellow or red zones. 
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Finally, Figure 6 shows an example patient with high glucose variability and high sensor error. The 
resulting Trend Compass shows a reduction in trend accuracy when compared to Figure 5, with a 
much wider angular spread of results (TI = 27.0°). Table 5 shows that this data set has 52% in the 
green zones, 8.7% in the yellow zones and 4.2% in the red zone. 
 
3.2 Clinical data 
Using clinical CGM data with paired BG measurements, the Trend Compass can quantify the level of 
trend accuracy allowing sensor performance to be evaluated and compared. The solid blue line in 
Figure 7 shows CGM sensor data and the red circles represent BG data from the same patient. 
Overall, the trend accuracy is very good and ~70% of the points lie in the green areas. Furthermore, 
Table 6 shows only 11.6% of points are in the yellow zone and only 1.4% in the red zone. The TI for 
this data set is 18.2° and this is potentially slightly skewed by a few outlier BG data points seen in the 
trace. Figure 8 uses the same data set as Figure 7, but with a 72mg/dL constant bias applied to CGM 
sensor data. The Trend Compass plot and TI in Figure 8 and the performance metric table in Table 7 
remain unchanged with the offset SG data, further illustrating the independence of this method 
from point bias error. 
 
Figure 9 shows the CGM data from Figures 7 and 8, coupled with BG measurements from a different 
data set. The trend accuracy is expected to be marginal because the SG/BG are sampled from 
different individuals and are independent. The Trend Compass shows a wide spread of points 
indicating poor trend accuracy and this is reinforced by the TI of 37. 2°. Sections A and C in Figure 9 
show periods of good trending and Section B shows a period of poor trend accuracy. The trend 
metrics shown in Table 8 report 34% of points are in the green zones, 13.6% in yellow and 3% in the 
red zones.   
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SG measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 91.3
Percent in yellow 0
Percent in red 0
When BG is rising BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 47.8 0 47.8
Percent outside green 0 4.3 0 4.3
When BG is falling BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 43.5 0 43.5
Percent outside green 0 4.3 0 4.3
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SG measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 39.1
Percent in yellow 0
Percent in red 8.7
When BG is rising BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 26.1 0 26.1
Percent outside green 0 26.1 0 26.1
When BG is falling BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 13 0 13
Percent outside green 8.7 26.1 0 34.8
Figure 3: (left) BG and SG measurements 
for a stable patient with low sensor error. 
(right) Trend Compass plot for this data set 
with TI metric. 
Table 2: Performance table showing trend 
accuracy for this data set 
Figure 4: (left) BG and SG measurements 
for a stable patient with high sensor error. 
(right) Trend Compass plot for this data set 
with TI metric. 
Table 3: Performance table showing trend 
accuracy for this data set 
 
TI = 28.1° 
TI = 11.3° 
14 of 23 
 
 
 
 
  
  
0 500 1000 1500
0
50
100
150
200
250
300
Time (mins)
B
lo
o
d
 g
lu
c
o
s
e
 (
m
g
/d
L
)
 
 
SG measurements
BG measurements
BG 
BG 
BG < SG BG > SG
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Overall trend accuracy
Percent in green 82.6
Percent in yellow 0
Percent in red 0
When BG is rising BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 13 30.4 43.5
Percent outside green 0 13 0 13
When BG is falling BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 13 26.1 39.1
Percent outside green 0 4.3 0 4.3
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SG measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 52.2
Percent in yellow 8.7
Percent in red 4.3
When BG is rising BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 4.3 26.1 30.4
Percent outside green 0 17.4 8.7 26.1
When BG is falling BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 4.3 8.7 8.7 21.7
Percent outside green 4.3 4.3 13 21.7
Figure 5: (left) BG and SG measurements 
for a variable patient with low sensor 
error. (right) Trend Compass plot for this 
data set with TI metric. 
Table 4: Performance table showing trend 
accuracy for this data set 
 
Figure 6: (left) BG and SG measurements 
for a variable patient with high sensor 
error. (right) Trend Compass plot for this 
data set with TI metric. 
Table 5: Performance table showing trend 
accuracy for this data set 
 
TI = 27.0° 
TI = 11.1° 
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Percent outside green 0 7.2 11.6 18.8
When BG is falling BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 26.1 4.3 30.4
Percent outside green 1.4 4.3 5.8 11.6
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BG measurements
CGM with 72mg/dL offset
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 69.6
Percent in yellow 11.6
Percent in red 1.4
When BG is rising BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 24.6 14.5 39.1
Percent outside green 0 7.2 11.6 18.8
When BG is falling BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 26.1 4.3 30.4
Percent outside green 1.4 4.3 5.8 11.6
Figure 7: (left) Clinical CGM data and BG 
measurements from the same subject. 
(right) Trend Compass plot for this data set 
with TI metric. 
Table 6: Performance table showing trend 
accuracy for this data set 
 
Figure 8: (left) Clinical CGM data with a 
72mg/dL bias and BG measurements from 
the same subject. (right) Trend Compass 
plot for this data set with TI metric. 
Table 7: Performance table showing trend 
accuracy for this data set 
 
TI = 18.2° 
TI = 18.2° 
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CGM measurements
BG measurements
A C
B
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 34.8
Percent in yellow 13.6
Percent in red 3
When BG is rising BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 1.5 12.1 3 16.7
Percent outside green 1.5 18.2 13.6 33.3
When BG is falling BG < 90mg/dL 90mg/dL < BG < 160mg/dL BG > 160mg/dL overall
Percent in green 0 13.6 4.5 18.2
Percent outside green 3 10.6 18.2 31.8
Figure 9: (left) Clinical CGM data and BG 
measurements from two different subjects. 
(right) Trend Compass plot for this data set 
with TI metric. 
Table 8: Performance table showing trend 
accuracy for this data set 
 
TI = 37.2° 
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4.0 Discussion 
The aim of this study was to develop a novel tool that could quantify the trend accuracy of CGM 
devices. The results present an intuitive plot that gives a quick visual assessment of relative CGM 
trend accuracy, and allows detailed quantified results for in-depth comparison. The Trend Compass 
is described in this manuscript with reference to SG data from a continuous glucose monitoring 
system that is compared to paired BG measurements from a reference method. It should be noted 
that error in reference BG measurements can have an impact on trend accuracy. In order to 
minimise this impact, it is recommended that a gold standard BG measurement device/method be 
used during the CGM monitoring period. 
 
With the introduction of CGM devices, trend accuracy has become very important due to increased 
investigation of closed loop glycemic control and the increased use of hypo/hyperglycemia alarm 
algorithms, which all inherently use trend patterns. The trend compass was not designed to replace 
conventional accuracy metrics such as MARD or the Bland Altman plot. In fact, it is intended to be 
used in conjunction with traditional measures of point sensor accuracy. Using error metrics 
alongside the Trend Compass gives the user much more useful information about the overall 
performance of a sensor. Equally, as an objective measurement of trend accuracy, the Trend 
Compass could potentially be useful for regulatory bodies when assessing sensor performance prior 
to approval. 
 
The results for the simulated data show how the Trend Compass can effectively differentiate 
between good trend accuracy and poor trend accuracy. Figures 3 and 4 assess the trend accuracy for 
a stable, with low glucose variability patient with different levels of sensor noise. Comparing the plot 
of SG-BG data for each patient it is difficult to determine which data has better trend accuracy, 
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although it is obvious that the data in Figure 3 has a lower sensor error. It is important that the 
Trend compass is able to differentiate between the trend accuracy of the two devices in a robust 
way. In this case with a simulated stable patient the Trend Compass clearly shows that the data in 
Figure 3 has better trend accuracy. This outcome extends to Figures 5 and 6 which show different 
sensor error levels for the same high glucose variability simulated patient. Again, the Trend compass 
is clearly able to show which sensor has better trend accuracy, in this case the data plotted in Figure 
5. 
 
Another aspect that needed to be robust is the impact of patient variability. Comparing Figure 3 to 
Figure 5, and Figure 4 to Figure 6, it is clear that the patient variability doesn’t impair the ability of 
the Trend Compass to reliably assess trend accuracy. This aspect is very important as different 
patients or cohorts can have very different glycemic dynamics, so the assessment of trend accuracy 
must be robust to these differences. Figures 3 and 5 show two different patient dynamics, but with 
similar levels of sensor error. The Trend Compass effectively conveys that in both cases the trend 
accuracy is very good. This is further reinforced with the accompanying performance table and TI 
metric. Figures 4 and 6 also show two different patient dynamics, but this time for a higher level of 
sensor error. Again, the Trend Compass is consistent in showing both data sets with moderate to 
poor trend accuracy. 
 
When using the Trend Compass with clinical data the usefulness of the method is immediately clear, 
as shown by comparing Figures 7,8 and 9. Figure 7, which contains well correlated data collected 
from one patient shows good trending compared to Figure 9 which contains uncorrelated data 
collected from two different individuals. The discrepancies between the trend accuracy of the two 
data sets can be easily interpreted from the Trend Compass plots alone. Interestingly, Table 8 shows 
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the Trend Compass for the uncorrelated data set still has ~35% of points in the green zones. This 
result is likely due to the sections marked ‘A’ and ‘C’ in Figure 9, which both show relatively good 
trending between SG and BG by chance.  
Figures 7 and 8 show how the Trend Compass can classify trend accuracy independent of point 
measurement bias error. The blue SG trace in Figure 8 is the same data as shown in Figure 7, but 
with a positive 72mg/dL offset. This offset significantly increases the point error, but the Trend 
Compass remains unchanged. This lack of change occurs because the relative slope between SG and 
BG has not changed with the offset, and that relative slope is the fundamental mechanism used to 
quantify trend with this method. This example further reinforces the intended use of the Trend 
Compass to assess solely trend accuracy in conjunction with traditional point measurement error 
metrics, creating a more complete assessment of sensor performance. 
 
The importance of assessing trend accuracy as a function of BG level is made clear by the paired BG-
SG measurements in section ‘B’ in Figure 9. The trend accuracy in section B falls within the red zone 
of the Trend Compass, because the BG is falling while the SG is reporting a rise in glucose at a 
substantially different rate. The implications of a drop in glucose being reported as a rise by a CGM 
device could be very dangerous, potentially leading to missed treatment of hypoglycemia. 
Furthermore, alarm algorithms that use trend information may not alert the user at the onset of 
these events. 
 
Finally, there is one limitation that should be noted when comparing blood and interstitial glucose 
concentrations, for either trend accuracy or point accuracy assessment. The interactions between 
the two compartments are not fully understood and discrepancies in glucose concentration may 
occur due to physiological effects. Thus, when point or trend accuracy metrics are used to assess 
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sensor performance, any physiological effects that may exist are ‘lumped in’ with actual sensor 
inaccuracies.   
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5.0 Conclusion 
The Trend Compass is a tool that can quantify trend accuracy between two devices measuring a 
single time series, such as a CGM device and a reference BG. It is robust when used with different 
patient cohorts (different dynamics), as well as different levels of sensor error. The resulting trend 
accuracy is easily interpreted on the Trend Compass plot, and if required, accompanying 
performance table and TI metric. Importantly, it assesses trend accuracy independent of BG level 
and point bias error. Thus, a device may have poor point accuracy, but excellent trend accuracy. 
Assessing trend accuracy is as important as assessing point measurement error as CGM devices 
become more widely used, and a tool such as the Trend Compass provides an easy to interpret, 
reliable method to do so. 
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 Appendix A 
 
 
 
Use top left 
quadrant of Trend 
Compass 
Use bottom right 
quadrant of Trend 
Compass 
Use top right 
quadrant of Trend 
Compass 
Use bottom left 
quadrant of Trend 
Compass 
Is BG2-BG1 ≥ 
SG2-SG1 
Is BG2-BG1 ≥ 
SG2-SG1 
 
Is BG2 ≥ BG1 
Use top hemisphere of 
Trend Compass 
Use bottom hemisphere 
of Trend Compass 
Calculate angle between a and b using Equation 2, then divide by 2*: 
 
 𝜃 =
𝑐𝑜𝑠−1 (
(𝑇2−𝑇1)
2 + (𝐵𝐺2−𝐵𝐺1) × (𝑆𝐺2−𝑆𝐺1)
√(𝑇2−𝑇1)2 + (𝐵𝐺2−𝐵𝐺1)2 × √(𝑇2−𝑇1)2 + (𝑆𝐺2−𝑆𝐺1)2
)
2
 
 
Plot a point on the Trend Compass: 
𝜃 – Degrees from the vertical 
r – Value of BG2 
 
Using The Trend Compass. 
For example if BG changes from BG1 at T1 to BG2 at T2 and 
SG changes from SG1 at T1 to SG2 at T2. Units for BG and SG 
should be converted to mmol/L and T to hours. 
 
We define a = [T2-T1, BG2-BG1] and b = [T2-T1, SG2-SG1] 
 
Yes 
 
No 
 
No 
 
Yes 
 
No 
 
Yes 
 
*Note: The angle (𝜃) is divided by 2 to give 𝜃 so the full range of theoretic angles can be displayed on each quadrant. The theoretical limit is BG 
rising vertically and SG falling vertically (or vice versa), which would result in 180° between the vectors (displayed as 𝜃=90° on the Trend Compass). 
